Advancing Brain Disease Treatment with Novel Tubulin Therapies

RGN6024 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers.

Greater than 50% of all ADCs use a microtubule targeting agent (MTA) as the payload. Reglagene has an expansive portfolio of 900+ MTAs, with outstanding potency. Reglagene is looking for a partner in this space who has expertise and specialization in the antibody and linker portion of the ADC.

Reglagene has multiple orally administered, blood-brain barrier penetrant microtubule targeting agents that have the unique ability of reducing neuro-inflammation and are being developed for the treatment of Parkinson's Disease.